Clinical performance of cerebrospinal fluid phospho-tau biomarkers for Alzheimer’s disease diagnosis

Takeaway

  • N-terminal directed phosphorylated tau 217 (N-p-tau217) and N-terminal directed phosphorylated tau 181 (N-p-tau181) may improve diagnostic accuracy in prodromal Alzheimer’s disease (AD) and clinical trial recruitment.

Why this matters

  • Phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) is an established AD biomarker; novel immunoassays targeting N-terminal and mid-region p-tau181 and p-tau217 fragments are now available, but head-to-head comparison between them in clinical settings is lacking.

  • N-p-tau217 and N-p-tau181 may constitute potential early diagnostic markers for prodromal AD, allowing for earlier, more appropriate intervention and improved outcomes for patients.